CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion

C. E. Hock, A. M. Lefer

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

A new thromboxane synthetase inhibitor, CGS-12970 was evaluated for its ability to reduce the extension of myocardial infarct size in rats. CGS-12970 was given at either 4 or 8 mg/kg following acute coronary artery ligation. Both myocardial creatine kinase (CK) and amino-nitrogen loss from the left ventricular free wall (LVFW) were used as indices of ischemic damage at 48 hours. Rats given only the vehicle following coronary artery ligation lost 4.9 ± 0.5 IU/mg protein (p < 0.001) CK activity from the LVFW. This loss of CK activity was only slightly reduced by CGS-12970 at 4 mg/kg. However, at 8 mg/kg, the CK depletion from the LVFW was significantly reduced (p < 0.05). This protective effect was confirmed by similar curtailment (p < 0.05) of the loss of nitrogenous compounds from ischemic myocardium, at the high dose of CGS-12970. These findings represent a protective effect of CGS-12970 in reducing the extent of ischemic cardiac damage following experimental coronary artery ligation.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalResearch Communications in Chemical Pathology and Pharmacology
Volume52
Issue number3
StatePublished - 1986
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Toxicology
  • Pharmacology
  • General Pharmacology, Toxicology and Pharmaceutics

Fingerprint

Dive into the research topics of 'CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion'. Together they form a unique fingerprint.

Cite this